Matastatic Cancer - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal of the radiographic progression-free survival target in test patients.

AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b

HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.

by HealthQuill
April 29, 2025
0 Comments

About Us

Contact Info

Follow Us

AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b